Becton, Dickinson and Company (BDX) Stake Lessened by Northeast Investment Management

Northeast Investment Management cut its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 35.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,329 shares of the medical instruments supplier’s stock after selling 1,822 shares during the period. Northeast Investment Management’s holdings in Becton, Dickinson and were worth $652,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the company. Sirios Capital Management L P raised its position in Becton, Dickinson and by 23.8% during the third quarter. Sirios Capital Management L P now owns 786,542 shares of the medical instruments supplier’s stock valued at $154,122,000 after buying an additional 151,186 shares during the period. Nippon Life Global Investors Americas Inc. raised its position in Becton, Dickinson and by 7.3% during the third quarter. Nippon Life Global Investors Americas Inc. now owns 67,800 shares of the medical instruments supplier’s stock valued at $13,286,000 after buying an additional 4,630 shares during the period. SevenBridge Financial Group LLC raised its position in Becton, Dickinson and by 5.2% during the third quarter. SevenBridge Financial Group LLC now owns 12,579 shares of the medical instruments supplier’s stock valued at $2,465,000 after buying an additional 622 shares during the period. BB&T Investment Services Inc. raised its position in Becton, Dickinson and by 43.2% during the third quarter. BB&T Investment Services Inc. now owns 9,869 shares of the medical instruments supplier’s stock valued at $1,966,000 after buying an additional 2,978 shares during the period. Finally, Stifel Financial Corp raised its position in Becton, Dickinson and by 1.8% during the third quarter. Stifel Financial Corp now owns 425,675 shares of the medical instruments supplier’s stock valued at $83,595,000 after buying an additional 7,332 shares during the period. 88.46% of the stock is currently owned by institutional investors.

Several research analysts recently weighed in on the company. Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a research report on Wednesday, August 9th. Cowen reissued a “buy” rating and set a $230.00 price target on shares of Becton, Dickinson and in a research report on Monday, August 14th. Barclays reissued an “equal weight” rating and set a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a research report on Thursday, August 10th. BidaskClub raised Becton, Dickinson and from a “hold” rating to a “buy” rating in a research report on Monday, August 14th. Finally, Zacks Investment Research lowered Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Monday, August 7th. Four equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $217.08.

In other news, insider Gary M. Cohen sold 15,512 shares of the company’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the sale, the insider now owns 95,781 shares in the company, valued at approximately $19,517,294.37. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Stephen Sichak sold 11,787 shares of the company’s stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $200.46, for a total value of $2,362,822.02. Following the sale, the insider now owns 14,038 shares of the company’s stock, valued at approximately $2,814,057.48. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company (BDX) opened at $218.92 on Tuesday. The company has a debt-to-equity ratio of 1.44, a current ratio of 5.58 and a quick ratio of 5.03. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $229.68. The company has a market capitalization of $49,910.00, a PE ratio of 23.85, a price-to-earnings-growth ratio of 1.77 and a beta of 1.06.

Becton, Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, beating analysts’ consensus estimates of $2.37 by $0.03. Becton, Dickinson and had a return on equity of 20.56% and a net margin of 8.52%. The firm had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.14 billion. During the same quarter in the previous year, the company posted $2.12 earnings per share. The business’s quarterly revenue was down 2.0% compared to the same quarter last year. equities research analysts forecast that Becton, Dickinson and Company will post 10.65 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be paid a $0.75 dividend. The ex-dividend date of this dividend is Thursday, December 7th. This represents a $3.00 dividend on an annualized basis and a yield of 1.37%. This is an increase from Becton, Dickinson and’s previous quarterly dividend of $0.73. Becton, Dickinson and’s payout ratio is 62.80%.

COPYRIGHT VIOLATION NOTICE: This report was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2017/12/05/becton-dickinson-and-company-bdx-stake-lessened-by-northeast-investment-management.html.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply